American College of Gastroenterology Annual Meeting

American College of Gastroenterology Annual Meeting

Source:

Singal A. Symposium: Hepatology 101. HCC 101- Screening, Surveillance, Treatment. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).

Disclosures: Singal reports consulting for Genentech, Bayer, Exelixis, AstraZeneca, Exact Sciences, Glycotest Inc., Roche, Fujifilm Pharmaceuticals, Medical Sciences and Grail.
October 24, 2021
1 min watch
Save

VIDEO: Multidisciplinary approach linked to higher survival in HCC

Source:

Singal A. Symposium: Hepatology 101. HCC 101- Screening, Surveillance, Treatment. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021; Las Vegas (hybrid meeting).

Disclosures: Singal reports consulting for Genentech, Bayer, Exelixis, AstraZeneca, Exact Sciences, Glycotest Inc., Roche, Fujifilm Pharmaceuticals, Medical Sciences and Grail.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LAS VEGAS – In this video exclusive from the ACG Scientific Annual Meeting, Amit Singal, MD, from UT Southwestern Medical Center, discussed best practices for the screening, surveillance, and treatment of hepatocellular carcinoma.

“One of the strongest drivers for patients with HCC is the tumor stage in which we detect the tumor with curative options available with patients with early-stage disease and palliative options with more advanced tumor burden,” he said.

Singal noted surveillance should include ultrasound with the alpha fetoprotein tumor marker test every 6 months in at-risk patients, including those with cirrhosis. This is correlated with significant improvement in early detection and improved survival.

Among the treatment options for HCC are surgical resection and liver transplantation for patients found at an early stage. This correlated with 5-year survival. In those with intermediate stage, local regional therapy is used, and systemic therapy is used in advanced stages.

“I touched upon the importance of multidisciplinary care, given the availability of multiple treatment options being delivered my multiple specialties,” he said. “This practice of multidisciplinary evaluation and care has been associated with improved outcomes most notably improved survival for patients with HCC.”